Immuno-Biological Laboratories: Notice of patent acquisition relating to “anti-HIV antibodies and their manufacturing methods”
Immuno-Biological Laboratories: Financial results for the first quarter of the 2025 fiscal year ending in March, under the Japanese standard (consolidated).
Immuno-Biological Laboratories: Announcements of individual stocks regarding the manufacturing and sales notification of in vitro diagnostic pharmaceuticals.
Immuno-Biological Laboratories: Corporate Governance Report June 26, 2024
Immuno-Biological Laboratories: Extraordinary Report
Immuno-Biological Laboratories: Internal Control Report - 42nd Term (2023/04/01 - 2024/03/31)
Immuno-Biological Laboratories: Confirmation letter
Immuno-Biological Laboratories: Securities report - 42nd period (April 1, 2023 - March 31, 2024)
Immuno-Biological Laboratories: Announcements of individual stocks: Exclusive licensing agreement signed for the SFTS virus antibody gene against severe fever with thrombocytopenia syndrome.
Immuno-Biological Laboratories: Regarding the correction of some of the numerical data in the "2024 Fiscal Year End Results Briefing (Japanese Standards, Consolidated)".
Immuno-Biological Laboratories: Announcements of individual stocks regarding the status of joining the Public Interest Incorporated Foundation Financial Accounting Standards Board and thoughts on joining.
Immuno-Biological Laboratories: Announcements of individual stocks related to compliance with listing maintenance standards.
Immuno-Biological Laboratories: Notice of Convocation of the 42nd Annual General Meeting of Shareholders and Shareholders' Meeting Materials
IMMUNO-BIOLOGICAL LABORATORIES: Explanation of business plans and growth potential
IMMUNO-BIOLOGICAL LABORATORIES: Financial results presentation materials for the fiscal year ending 2024/3 (42nd term)
IMMUNO-BIOLOGICAL LABORATORIES: Summary of Financial Results for the Fiscal Year Ending March 31, 2024 [Japanese GAAP] (Consolidated)
IMMUNO-BIOLOGICAL LABORATORIES: Notice regarding the recording of book value devaluation of fixed assets (return of operating expenses), non-operating income, extraordinary losses, and corporate tax adjustments
IMMUNO-BIOLOGICAL LABORATORIES: Notice regarding revisions to full-year earnings forecasts
Immuno-Biological Laboratories: Notice Concerning Patent Acquisition
Immuno-Biological Laboratories: Notice regarding the start of manufacture and sale of the research reagent “Human Uromodulin ELISA Kit-IBL”
No Data
No Data